Q-omics provides the consensus-scored MIR4641 profile across patient tissues and cancer cell-line models. MIR4641 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MIR4641 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, MIR4641 RNA expression shows 9,815 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, COAD, and ESCA as cancer lineages where MIR4641 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4641 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4641 survival associations across molecular data types. MIR4641 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4641 RNA expression–survival associations across cancer types. High MIR4641 expression shows unfavorable associations in KIRC, MESO, UCEC, UVM and CHOL, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MIR4641 RNA expression.
This table summarizes MIR4641 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4641. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4641 shows higher tumor expression in COAD, UCEC and STAD. The COAD box plot shows higher MIR4641 RNA expression in tumor versus normal tissue (log2 FC = +0.597, t-test p < 0.001).
This table shows molecular features associated with MIR4641 in patient tissues and cancer cell lines. In patient samples, MIR4641 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
